The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes
Compounders offering versions of Novo Nordisks and Eli Lillys GLP-1 drugs have leaned on a "personalisation" argument to justify their activities, asserting that dose tweaks, added nutrients, or alternative delivery methods place their products within legal limits.
The Genesis: From Insulin to Incretins For nearly a century, metabolic health focused almost exclusively on insulin
Third, assess if your current dose remains optimal or if you need an increase
www.sciencedaily.com Elderly adults, especially those living in nursing homes, often have impaired immune function, which increases their susceptibility to respiratory infections and subsequent pneumonia
Taking these medications individually or in combination may lead to potential side effects